Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

164 trials

NCT07292961
Recruiting
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Not applicable · 1 site
Registry update: 18 Dec 2025
2024-518528-54-00
Recruiting
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Phase 1 · Germany, Spain, France · 13 sites
Registry update: 17 Aug 2026
NCT07305116
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · China · 1 site
Registry update: 3 Feb 2026
NCT07403188
Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase 2/3 · Germany, United States · 5 sites
Registry update: 11 Feb 2026
NCT07077304
Recruiting
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Not applicable · France · 1 site
Registry update: 5 Jun 2026
2025-523061-22-00
Recruiting
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
Phase 2 · Germany · 1 site
Registry update: 2 Oct 2026
NCT07085104
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Phase 1 · Canada, United States · 18 sites
Registry update: 2 Nov 2026
NCT07236801
Recruiting
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · China · 1 site
Registry update: 2 Mar 2026
NCT07090226
Recruiting
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
Not applicable · United States · 1 site
Registry update: 23 Jul 2026
NCT07245238
Recruiting
Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma
Phase 3 · Thailand · 1 site
Registry update: 24 Nov 2025
NCT07641634
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Phase 1/2 · Australia, China, South Korea, Mexico · 13 sites
Registry update: 9 Oct 2026
NCT06599411
Recruiting
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Not applicable · France · 1 site
Registry update: 12 Jun 2026
NCT07112183
Recruiting
Open Label Treprostinil Raynaud's Study
Phase 4 · United States · 1 site
Registry update: 24 Mar 2026
NCT07228429
Recruiting
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
Not applicable · United States · 1 site
Registry update: 4 Nov 2026
NCT07167537
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
Phase 1 · China · 1 site
Registry update: 11 Sept 2025
NCT07193810
Recruiting
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 14 Apr 2026
NCT07115745
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Phase 1 · Australia, Brazil, Czechia, Germany, Spain, France, Israel, Poland, Romania, United States · 28 sites
Registry update: 14 Jul 2026
NCT07343115
Recruiting
Familial Systemic Scleroderma
Not applicable · France · 1 site
Registry update: 15 Jan 2026
2025-520483-17-01
Recruiting
Efficacy and safety of repeated Rituximab infusions in patients with Active Systemic SClerosis and background medication, a one year randomized blinded placebo-controlled trial, the RASSc study.
Phase 4 · Netherlands · 3 sites
Registry update: 25 Nov 2025
NCT07184450
Recruiting
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Phase 1 · China · 1 site
Registry update: 19 Sept 2025

Ordered by registry start date. Freshness and sponsorship never change the order.